A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Clinical trial NCT02423343 · COMPLETED

Trial details

NCT number: NCT02423343
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor Non-Small Cell Lung Cancer Recurrent Hepatocellular Carcinoma Recurrent

Start date: 2015-01-01
Primary completion: 2018-12-13
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.